Area of research
Hematology · Molecular Biology
Research interest
Research focused on Multiple myeloma and Minimal residual disease, with related work in CYP1B1, Thalidomide, Placebo. Notable publications include 'International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma', 'International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders', and 'Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation'.
Phase II study of zevorcabtagene autoleucel, a fully human BCMA-targeting CAR T cell therapy, in patients with relapsed/refractory multiple myeloma
Updated survival outcomes of pomalidomide/bortezomib/dexamethasone in newly diagnosed multiple myeloma with renal impairment: A prospective, open-label, multicenter, phase 2 study
Renal response of selinexor, bortezomib, pomalidomide, and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: A phase 2, prospective, multicenter study
Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study
Expert consensus on a multidisciplinary approach for the management of multiple myeloma-related bone disease
SG301, a Novel Anti-CD38 Monoclonal Antibody, in Patients with Relapsed/Refractory Multiple Myeloma: A First-in-Human, Multicentre, Phase 1 Trial
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
High Risk Cytogenetic Abnormalities Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients Received Autologous Hematopoietic Cell Transplantation
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
Aponermin or placebo in combination with thalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (CPT-MM301): a randomised, double-blinded, placebo-controlled, phase 3 trial
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myeloma
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment
Expert consensus on microtransplant for acute myeloid leukemia in elderly patients -report from the international microtransplant interest group
Renal Response of Selinexor, Pomalidomide, Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Expert consensus on the bone repair strategy for osteoporotic fractures in China
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma
Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study
Treatment and outcome patterns of patients with Waldenström’s macroglobulinemia: a large, multicenter retrospective review in China
α-naphthoflavone-derived cytochrome P450 (CYP)1B1 degraders specific for sensitizing CYP1B1-mediated drug resistance to prostate cancer DU145: Structure activity relationship
Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-523 in Adult Patients with Primary Immune Thrombocytopenia: A Randomized, Double-Blind and Placebo-Controlled Phase 1b Study
A gulose moiety contributes to the belomycin (BLM) disaccharide selective targeting to lung cancer cells
P-192: Circularly permuted TRAIL (CPT) combined with Thalidomide and Dexamethasone in patients with relapsed/refractory Multiple Myeloma: a randomized, double-blind, placebo-controlled phase 3 study
Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation
Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation
Waldenström's Macroglobulinaemia in the Modern Era: Real World Outcomes and Prognostication across 35 Chinese Academic Hospitals
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders